Precision BioSciences swings to Q4 profit on Novartis milestone
Precision BioSciences (NASDAQ:DTIL) reported a sharp swing to profitability in its final quarter of 2025, a result primarily driven by the recognition of deferred revenue from its heavyweight partnerships in the genome-editing space.





-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)










-1-640x359.jpg&w=1200&q=75)


